Dynamic Vessel Analyzer (DVA) – a new method to detect endothelial dysfunction in chronic heart failure: correlation between DVA and asymmetric dimethyl arginine (ADMA) by Schwefer, Markus et al.
POSTER PRESENTATION Open Access
Dynamic Vessel Analyzer (DVA) – a new method
to detect endothelial dysfunction in chronic heart
failure: correlation between DVA and asymmetric
dimethyl arginine (ADMA)
Markus Schwefer
1*, Aleksandra Mandecka
2, Helen Schmicker-Helf
1, Andreas Brückmann
3, Thomas Lehmann
4,
Ingeburg Schauer
5, Frank Kramer
6, Marcus Blum
7, Harald Lapp
8
From 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Halle, Germany. 24-26 June 2011
Background
Chronic heart failure (CHF) is the leading cause of hos-
pitalization and death in industrialized countries. CHF is
frequently associated with humoral and metabolic dis-
turbances, including reduced bioavailability of the
important signalling molecule nitric oxide (NO), which
has vasodilating properties. Several studies reported high
plasma levels of asymmetrical NG, NG-dimethyl-L-argi-
nine (ADMA), an endogenous inhibitor of NO produc-
tion, in CHF, contributing to endothelial dysfunction.
The Dynamic Vessel Analyzer (DVA) enables dynamic
analyses of retinal vessels. NO is a mediator of retinal
vasodilator response to flicker light. Reduced response
of retinal arterioles to flicker light may be an attractive
technique to non-invasively assess endothelial dysfunc-
tion. The aim of the study was to test the hypothesis
that retinal vessel response to flicker light is reduced in
patients with CHF and correlates inversely with serum
ADMA levels.
Methods and results
16 patients with non-ischemic cardiomyopathy and 22
healthy volunteers were included. Retinal arteriolar
flicker response as percent change from baseline and
serum ADMA level were measured.
Retinal arteriolar flicker response was significantly
reduced in CHF patients compared to the healthy con-
trol group (Median: 0.60 vs. 4.60%; p<0.001). ADMA
levels tended to be higher in CHF patients (median: 0.66
vs. 0.62 μmol/L; p=0.099). Noteworthy, we observed a
highly significant inverse correlation between retinal
arteriolar flicker response and ADMA levels (r = -0.531,
p=0.001).
Conclusions
Our findings suggest that analysis of retinal vessels
could be an attractive non-invasive method to quantify
endothelial dysfunction in CHF.
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